Masatoshi Kudo - Concepedia

Author

Masatoshi Kudo

Also Known As

A.-L. Cheng, Byung-Cheol Song, Chih-Hung Hsu, Croce', Department Of Ultrasound, Fabio Piscaglia, Guang-Jian Liu, Hwi Young Kim, Ijin Joo, K Ikekubo

2.8K

Publications

124K

Citations

142

H-Index

401

Concepts

All Affiliations

Kindai University Musashino Red Cross Hospital National Taiwan University Hospital National Cancer Center Hospital East Kyoto University

About

Masatoshi Kudo is an author at Kindai University specializing in medicine, hepatology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	63	194	34.1K
2	Engineering	23	36	1.5K
3	Arts	1	1	13
4	Language Studies	1	1	31
5	Management	1	1	13

Masatoshi Kudo

832

Publications

93.9K

Citations

124

H-Index

Page 1

	Year	Citations
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma Richard S. Finn, Shukui Qin, Masafumi Ikeda, New England Journal of Medicine	2020	6.8K
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial Masatoshi Kudo, Richard S. Finn, Shukui Qin, The Lancet HepatologyMedicineRandomised Phase 3Clinical TrialsPathology	2018	5.3K
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau, The Lancet HepatologyMedicineExpansion TrialLiver CancerAdvanced Hepatocellular Carcinoma	2017	4.2K
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial Jordi Bruix, Shukui Qin, Philippe Merle, The Lancet HepatologyMedicineSorafenib TreatmentClinical TrialsPharmacotherapy	2016	3.6K
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial Andrew X. Zhu, Richard S. Finn, Julien Edeline, The Lancet Oncology Open-label Phase 2HepatologyMedicineClinical TrialsPathology	2018	2.5K
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle, Journal of Clinical Oncology	2019	1.8K
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen, The Lancet Oncology OncologyHepatologyα-Fetoprotein ConcentrationsClinical TrialsPathology	2019	1.6K
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda, Journal of Hepatology HepatologyAtezolizumab Plus BevacizumabUnresectable Hepatocellular CarcinomaMedicineImmunology	2021	1.5K
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo, NEJM Evidence	2022	1.3K
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study Joong‐Won Park, Minshan Chen, M. Colombo, Liver International	2015	1.2K

Page 1